BMS

Oct 20, 2023

New Player in Ulcerative Colitis Treatment: Pfizer’s Etrasimod Entry Counters BMS’ Zeposia

Feb 15, 2021

The Paradox of Rare: Chalking out Challenges in the Rare Disease Market

Aug 10, 2017

Bristol-Myers Squibb to nix; Pfizer commits $100M; Merck and GSK production issues; Shire unloads plant

May 30, 2017

Roche, Boehringer tout; Pfizer, Bristol-Myers got sued; FDA commissioner unveils; EpicGenetics expands

May 09, 2017

Lilly moves ahead; Authorities raid; Bristol-Myers, AZ in legal; PhRMA expected to weed out

May 04, 2017

Merck’s Keytruda sales; Valeant on name change; Pfizer – BMS; Amgen puts Repatha outcomes for deal

Feb 20, 2017

Diminishing pipeline of Galectin Inhibitors

Newsletter/Whitepaper